Trial Profile
A phase 1/2 study of the combination of pixantrone, etoposide, bendamustine and, in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T-cell phenotype - the P[R]EBEN study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Etoposide (Primary) ; Pixantrone (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PREBEN
- 12 Oct 2021 Planned primary completion date changed from 1 Feb 2021 to 1 Feb 2022.
- 09 Sep 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Feb 2021.
- 09 Sep 2020 Status changed from recruiting to active, no longer recruiting.